As of Thursday, January 29, Nautilus Biotechnology, Inc.’s NAUT share price has dipped by 5.58%, which has investors questioning if this is right time to buy.
Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy recommendation. As of December 23, 2024, the average one-year price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results